Presently, research is limited to animal studies, and some debates persist, resulting in insufficient clinical evidence to support circadian rhythm regulation or Bmal1-targeted therapies for acute kidney injury and chronic kidney disease. This evidence concerns the gene BMAL1 and chronic kidney disease.